BIO 2016 session preview: “No Patent, No Cure”

Effective patent protection is one of the key drivers of the research-intensive high-tech biotechnology sector (including start-ups and small and medium-sized enterprises), which stands out as one of the global industries with the highest percentage of sales re-invested in research and development.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

CREATES Act unfairly tips the scales to generics

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

‘A marathon and a sprint at the same time’: How we won $452m damages

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Trump’s return sparks calls for pro-patent agenda

Amgen faces pushback over bid to narrow patent scope

LSPN Europe: Navigating the EPO and lessons from the UPC frontline

BIO 2016 session preview: “No Patent, No Cure”

Editor's picks

Editor's picks

More features